Drug Selection in Canine Bph: Mechanisms, Efficacy, and Clinical Decision-Making

Article

GnRH Antagonists Delmadinone Acetate Prostate Management

Drug Selection in Canine Bph: Mechanisms, Efficacy, and Clinical Decision-Making

The management of canine benign prostatic hyperplasia (BPH) relies heavily on pharmacological intervention, particularly in cases where fertility preservation is required. Given the variety of available therapeutic agents, understanding their mechanisms of action, clinical efficacy, and potential reproductive implications is essential for informed decision-making. Since BPH is a hormonally driven condition, most treatments aim to modulate androgenic or estrogenic pathways that influence prostatic growth¹.

Hormonal Basis Guiding Drug Selection

The pathogenesis of BPH is closely associated with the conversion of testosterone into dihydrotestosterone (DHT) through the enzymatic activity of 5α-reductase^1,2. DHT plays a central role in promoting prostatic cellular proliferation, particularly in the hyperplastic component of the disease³. Estrogen further contributes by increasing androgen receptor expression and stimulating stromal proliferation, thereby enhancing the prostate’s responsiveness to androgens^1,4. These mechanisms form the basis for most pharmacological strategies used in BPH management.

5α-Reductase Inhibitors

Finasteride is a competitive inhibitor of 5α-reductase that reduces DHT levels without directly binding to androgen receptors. This selective action contributes to its relatively limited impact on reproductive function. Clinical studies have shown that finasteride effectively alleviates BPH symptoms within 30 days of treatment when administered at doses ranging from 0.1 to 0.5 mg/kg SID. However, reduction in prostate size is gradual, with significant changes typically observed after 60 days of therapy^1,5.

The degree of prostate shrinkage is influenced by dosage and duration. Higher doses, such as 1 mg/kg SID, have demonstrated faster and more pronounced effects, achieving up to a 47–54% reduction in prostate volume after 12 weeks¹. In contrast, lower doses produce more variable outcomes over similar timeframes¹. Finasteride also leads to a significant reduction in DHT levels in both serum and prostatic tissue while maintaining relatively stable testosterone levels. Additionally, it reduces serum CPSE levels, reflecting its impact on prostatic activity¹.

Epristeride, another 5α-reductase inhibitor, differs in that it acts as a noncompetitive inhibitor. It has been shown to reduce DHT levels in both serum and prostatic tissue, similarly to finasteride, while exerting a comparatively smaller effect on testosterone concentrations¹. This distinction suggests a potentially reduced impact on spermatogenesis, although further data in dogs remain limited.

Steroidal Antiandrogens

Osaterone acetate is a steroidal antiandrogen widely used in dogs for BPH treatment. Its mechanism involves blocking androgen receptors and reducing testosterone uptake within the prostate¹. This results in rapid clinical improvement, often observed shortly after completion of a seven-day treatment regimen⁶. Remission rates are high, ranging from 82.6% to 100%, with significant reductions in prostate volume documented as early as 14 days after treatment initiation^1,6.

Despite its efficacy, the therapeutic effects of osaterone acetate are temporary, and relapse may occur within several months, necessitating retreatment. The treatment also induces vascular changes within the prostate, including reduced tissue perfusion and altered blood flow parameters. Additionally, improvements in ultrasonographic structure and reduction in cyst size have been reported¹.

Chlormadinone acetate and delmadinone acetate belong to the class of progestogens and function as synthetic steroidal antiandrogens. These agents reduce the intracellular uptake of testosterone by competitively binding to androgen receptors. Chlormadinone acetate produces dose-dependent reductions in prostate size and induces apoptosis in prostatic tissue, leading to regression of both glandular and stromal components. Delmadinone acetate, administered via injection, provides a faster therapeutic response, achieving significant reductions in prostate volume within 14 days and sustained improvement over time¹. However, both agents require cautious use due to limited information regarding their effects on reproductive parameters.

GnRH Antagonists

GnRH antagonists, such as acyline and linzagolix, act by suppressing testosterone production at the hypothalamic-pituitary level. A single administration of acyline has been shown to reduce prostate volume by approximately 38.44%, with clinical signs resolving within 15 days. Similarly, linzagolix produces a 41% reduction in prostate weight after four weeks of treatment. However, the duration of effect is relatively short, with parameters returning to baseline within 60 days in the case of acyline¹.

Estrogen-Modulating Therapies

Tamoxifen is a nonsteroidal antiestrogen that competitively blocks estrogen receptors, leading to a reduction in prostate volume. Clinical studies have demonstrated rapid decreases in prostate size during treatment; however, these effects are not sustained, with prostate size returning to baseline within weeks after discontinuation. Anastrazole, an aromatase inhibitor, reduces the conversion of androgens to estrogens, thereby altering the estrogen-testosterone balance. This mechanism has been shown to produce significant reductions in prostate volume during treatment without affecting reproductive parameters^1,7.

Emerging and Alternative Therapies

Other therapeutic options include tadalafil, a phosphodiesterase-5 inhibitor, which has demonstrated reductions in prostatic markers such as CPSE and PSA without affecting blood parameters. Mepartricin, a compound that reduces circulating estrogen levels, has been shown to decrease stromal proliferation and prostate size in dogs. Additionally, Urtica fissa extracts exhibit 5α-reductase inhibitory activity and have demonstrated modest reductions in prostate volume¹. However, further research is required to establish their clinical utility.

Conclusion

The selection of pharmacotherapy for canine BPH should be guided by a thorough understanding of drug mechanisms and their clinical effects. While multiple agents are available, their efficacy, duration of action, and potential impact on reproductive function vary considerably. A tailored approach, supported by regular monitoring, is essential to achieve optimal therapeutic outcomes.

References:

Posastiuc FP, Constantin NT, Domain G, Soom AV, Diaconescu AI, Codreanu MD. A systematic review of medical treatments for benign prostatic hyperplasia in dogs: Evaluating strategies for reproductive function preservation. Veterinary sciences. 2025 Jan 19;12(1):70. https://doi.org/10.3390/vetsci12010070

Cunto M, Mariani E, Anicito Guido E, Ballotta G, Zambelli D. Clinical approach to prostatic diseases in the dog. Reproduction in Domestic Animals. 2019 Jun;54(6):815-22. https://cris.unibo.it/bitstream/11585/740379/1/Clinical%20approach%20-%20Cunto%20et%20al.pdf

Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S, Hoshi S, Sato Y, Ogawa S, Uemura M, Kojima Y. Mechanism of androgen-independent stromal proliferation in benign prostatic hyperplasia. International Journal of Molecular Sciences. 2023 Jul 19;24(14):11634. https://www.mdpi.com/1422-0067/24/14/11634

Chen B, Cao D, Chen Z, Huang Y, Lin T, Ai J, Liu L, Wei Q. Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia. Translational Andrology and Urology. 2020 Apr;9(2):322. https://pmc.ncbi.nlm.nih.gov/articles/PMC7214965/pdf/nihpp-rs4169007v1.pdf

Angrimani DS, Francischini MC, Brito MM, Vannucchi CI. Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PloS one. 2020 Jun 25;15(6):e0234714. https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0234714&type=printable